MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Psychosis"

  • MDS Virtual Congress 2020

    Increased risk of Parkinson’s disease in patients with schizophrenia spectrum disorders

    T. Kuusimäki, H. Al-Abdulrasul, S. Kurki, J. Hietala, S. Hartikainen, M. Koponen, A. Tolppanen, V. Kaasinen (Turku, Finland)

    Objective: To investigate the coincidence of Parkinson’s disease (PD) and schizophrenia spectrum disorders (SCD). Background: PD is characterized by a progressive loss of mesostriatal dopamine…
  • MDS Virtual Congress 2020

    Homer1 polymorphism in patients with Parkinson’s disease and psychosis

    A. Lenka, S. Vadivel, R. Christopher, S. Arumugham, S. Hegde, R. Yadav, P. Pal (Washington, DC, USA)

    Objective: To explore the association of psychosis in Parkinson’s disease with polymorphisms of HOMER1, a gene whose product (Homer1) is responsible for modulating the metabotropic…
  • MDS Virtual Congress 2020

    Attitudes of Care Partners Toward Medications for Parkinson’s Disease Psychosis

    S. Mantri, S. Albert, E. Klawson, L. Alzyoud, M. Daeschler, C. Kopil, C. Marras, L. Chahine (Toronto, ON, Canada)

    Objective: To explore attitudes regarding use of medications among care partners of individuals with Parkinson’s disease psychosis. Background: Parkinson’s disease (PD) psychosis is a highly…
  • MDS Virtual Congress 2020

    Mental Health Matters Too – Integration of physical and mental health in a multidisciplinary Parkinson’s Clinic

    C. Taylor, C. Johnson, J. Marsh, L. Brown, A. Silverwood, R. Stringer, C. Cooper, R. Skelly (Derby, United Kingdom)

    Objective: The overall aim of the project was to demonstrate that people with Parkinson’s disease benefit from good mental health care when mental health services…
  • 2019 International Congress

    Healthcare Resource Utilization and Costs of Parkinson’s Disease Dementia With Psychosis in the US Medicare Population

    J. Wetmore, H. Yan, M. Irfan, Y. Peng, D. Gilbertson, S. Li, N. Rashid, A. Shim (Minneapolis, MN, USA)

    Objective: To describe healthcare resource use (HCRU) and related costs among Parkinson’s patients with dementia (PDD) and psychosis compared with other dementia types in a…
  • 2019 International Congress

    Predictors of Retention for Carbidopa/Levodopa Intestinal Gel in Parkinson Disease

    A. Nagy, T. Davis, T. Hassell, P. Hedera, D. Isaacs, H. Koons, F. Phibbs, S. Afrow, J. Fang (Nashville, TN, USA)

    Objective: To identify predictors of discontinuation of levodopa/carbidopa intestinal gel therapy. Background: Although levodopa/carbidopa intestinal gel (LCIG) is an established treatment for Parkinson's disease complicated…
  • 2019 International Congress

    Identifying delirium in people with Parkinson’s disease: the Determine-PD pilot study

    R. Lawson, S. Richardson, A. Yarnall, D. Burn, L. Allan (Newcastle Upon Tyne, United Kingdom)

    Objective: To identify the prevalence of delirium in inpatients with Parkinson’s disease (PD). Background: People with PD may be at increased risk of delirium and…
  • 2019 International Congress

    Comparison of Dementia Patients With and Without Parkinson’s Disease Before Dementia-related Psychosis Occurs: An Administrative Claims Data Analysis

    A. Shim, B. Skoog, V. Abler, N. Rashid, R. Halpern, E. Koep, M. Frazer (San Diego, CA, USA)

    Objective: Describe and compare patients with evidence of dementia-related psychosis diagnosed with Parkinson’s disease with dementia (PDD) versus patients with dementia but no Parkinson’s disease…
  • 2019 International Congress

    Subacute Encephalopathy with Pimavanserin Treatment in Parkinson Disease

    J. King, G. Volkell, J. Wyant, E. Molho (Albany, NY, USA)

    Objective: To report 3 cases of drug-induced encephalopathy in patients treated with pimavanserin (PVN) for Parkinson disease (PD) related psychosis (PDP). Background: Quetiapine and clozapine,…
  • 2019 International Congress

    Electroconvulsive Therapy (ECT): An Effective Option for the Treatment of Medication-Resistant Psychiatric Symptoms in Huntington’s Disease: A Case Series and Review of the Literature

    J. Adrissi, N. Nadkarni, E. Gausche, D. Bega (Chicago, IL, USA)

    Objective: Through a single site case series, we investigate the use and effectiveness of electroconvulsive therapy (ECT) for the treatment of refractory psychiatric symptoms in…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 14
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley